|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (IN.TO, Toronto Stock Exchange) |
Company Size: |
10-19 Employees In BC (10-19 Total)
10-19 In BC (10-19 Total)
|
Year Founded: |
2014 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
InMed, cannabinoid-based pharmaceutical products
|
|
|
Based in Vancouver, British Columbia, Canada, InMed's strategic focus is the development of prescription, cannabinoid-based pharmaceutical products. We commenced our current activities in May, 2014, upon the acquisition of a privately-held British Columbia based biopharmaceutical company focused on the drug discovery and development of cannabinoid compounds.
In the ensuing years, our leadership team has taken numerous steps and corporate actions to de-risk and solidify our capital structure, fortify our cash position and liquidity, assemble a world class leadership team with a successful track record in drug development, strengthen our potentially game-changing bioinformatics and biosynthesis platform technologies, and deploy and advance our cannabinoid-based pipeline of drug candidates across a spectrum of diseases with high unmet medical needs.
Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any others.
|
|
|
Date |
Type |
Amount |
Investors |
Jun 23, 2020 |
Private Placement |
$12 Million USD |
|
Date |
Type |
Amount |
Investors |
Jun 23, 2020 |
Private Placement |
$12M USD |
|
|
|
Want More InMed Pharmaceuticals Inc. News? 1
|
Next »
|
|
|
|
|
Jan 8, 2021
|
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755
|
Jun 25, 2020
|
InMed Introduces IntegraSyn: An Integrated Cannabinoid Manufacturing System
|
Jun 24, 2020
|
InMed to Raise $12 Million US Financing, Makes Application to Seek Nasdaq Listing and Consolidate Shares
|
May 26, 2020
|
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
|
May 12, 2020
|
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
|
Jan 8, 2020
|
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolys
|
Dec 19, 2019
|
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
|
Jun 25, 2018
|
Vancouver-based Inmed Pharmaceuticals Closes $15 Million Financing
|
|
|
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|